CD80 insights as therapeutic target in the current and future treatment options of frequent-relapse minimal change disease

• Main Authors: Teh, Yoong Mond, Lim, Soo Kun, Jusoh, Norhana, Osman, Kahar, Mualif, Siti Aisyah
• Format: Article
• Language: English
• Published: Hindawi Limited 2021
• Subjects: Q Science (General); R Medicine (General)
• Online Access: http://eprints.utm.my/id/eprint/95967/1/NorhanaJusoh2021_CD80InsightsasTherapeuticTargetintheCurrentandFuture.pdf; http://eprints.utm.my/id/eprint/95967/; http://dx.doi.org/10.1155/2021/6671552
• Institution: Universiti Teknologi Malaysia

Minimal change disease (MCD) is the most common cause of idiopathic nephrotic syndrome in children, and it is well known for its multifactorial causes which are the manifestation of the disease. Proteinuria is an early consequence of podocyte injury and a typical sign of kidney disease. Steroid-sensitive patients react well with glucocorticoids, but there is a high chance of multiple relapses. CD80, also known as B7-1, is generally expressed on antigen-presenting cells (APCs) in steroid-sensitive MCD patients. Various glomerular disease models associated with proteinuria demonstrated that the detection of CD80 with the increase of urinary CD80 was strongly associated closely with frequent-relapse MCD patients. The role of CD80 in MCD became controversial because one contradicts finding. This review covers the treatment alternatives for MCD with the insight of CD80 as a potential therapeutic target. The promising effectiveness of CD20 (rituximab) antibody and CD80 inhibitor (abatacept) encourages further investigation of CD80 as a therapeutic target in frequent-relapse MCD patients. Therapeutic-based antibody towards CD80 (galiximab) had never been investigated in MCD or any kidney-related disease; hence, the role of CD80 is still undetermined. A new therapeutic approach towards MCD is essential to provide broader effective treatment options besides the general immunosuppressive agents with gruesome adverse effects.